Clinical Trial Update: Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years. [Phase 2]

View source ↗

Summary

A Phase 2 study comparing vaccine GSK134612 with Menactra in healthy adolescents and young adults (10-25 years) assessed immunogenicity and safety. Results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• GSK134612 (Meningococcal vaccine)
• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED | Results posted: 2017-04-12